whitepaper
Product hub: Stay at the forefront of neuroscience research
Read about our comprehensive portfolio of rigorously developed kits harnessing the ultrasensitive Single Molecule Counting (SMC™) technology.
List view / Grid view
Neurosciences
news
Mechanism that causes ALS nerve destruction unveiled for first time
The study reveals the biological mechanism that causes nerve destruction in amyotrophic lateral sclerosis (ALS), potentially leading to treatments that reverse the disease.
article
Drug Target Review – Issue 4 2021
This issue includes articles that discuss the development of long-term 3D tissue cultures from human biopsy samples, the application of flow cytometry in drug discovery and automation for upstream processing in a biologics manufacturing environment. Also included are features on informatics, proteomics and CRISPR.
news
New Oxford-GSK Institute aims to unravel complex diseases
GlaxoSmithKline (GSK) and the University of Oxford will collaborate to investigate diseases using technologies such as functional genomics and machine learning.
news
Drug intended to treat Alzheimer’s may hold promise for glioblastoma
Verubecestat demonstrated poor results in Alzheimer's trials, but helped suppress tumours in pre-clinical glioblastoma models.
news
New target for overeating identified in the brain’s cerebellum
The study uncovered disordered signalling in the brain's cerebellum, offering a novel therapeutic target for Prader Willi syndrome.
news
Scientists explore CA2 neuron mitochondria for memory loss targets
The team will receive $2 million over five years to investigate the CA2 brain region for the development of neurological therapies.
news
Soluble fibrinogen a potential target for neurodegeneration
In a pre-clinical study, fibrinogen increased the death of mouse brain neurons, suggeting fibrin can have similar toxic effects on neurons.
news
ABI3 gene may be the key to new Alzheimer’s disease therapies
The study found that deleting the ABI3 gene in mice increased plaques and inflammation in the brain, suggesting avenues for new treatments.
news
Alterity’s ATH434 improves Parkinson’s-related gastrointestinal dysfunction
ATH434 reversed some of the gastrointestinal damage to the enteric nervous system associated with Parkinson's disease in a pre-clinical study.
news
Gene therapy bolsters Parkinson’s drug benefits in pre-clinical study
The gene therapy restored the ability of neurons to convert levodopa to dopamine and may help develop therapies to slow disease progression.
news
Scientists eliminate key Alzheimer’s feature in animal model
Turning off NHE6 in mice in pre-clinical studies prevented amyloid beta aggregation, a key feature of Alzheimer's disease, pointing to new therapies.
news
$9 million grant awarded to uncover whether Parkinson’s starts in the nose
A new grant will allow an international team to determine if scent-processing nerves in the nose play a role in the development of Parkinson's and could aid in the development of novel therapeutics.
news
Gene therapy shows promise for Angelman syndrome treatment
A new gene therapy restored motor skill-learning and usual behaviours in Angelman syndrome mouse models, suggesting a novel therapy for the condition.
news
Scientists identify protein that prevents HSV-1 brain damage
Mammalian target of rapamycin complex 2 (mTORC2) was found to prevent brain damage in mice infected with herpes simplex virus 1 (HSV-1).
